

# CITATION REPORT

List of articles citing

Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials

DOI: 10.1371/journal.pone.0004944  
PLoS ONE, 2009, 4, e4944.

**Source:** <https://exaly.com/paper-pdf/46870699/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
352	Comparative analysis of the widespread and conserved PB1-like viruses infecting <i>Pseudomonas aeruginosa</i> . <b>2009</b> , 11, 2874-83		69
351	Isolation and characterization of bacteriophages infecting <i>Staphylococcus epidermidis</i> . <b>2010</b> , 61, 601-8		43
350	The SPO1-related bacteriophages. <b>2010</b> , 155, 1547-61		78
349	Bacteriophages as potential new therapeutics to replace or supplement antibiotics. <b>2010</b> , 28, 591-5		321
348	Characterization of JG024, a <i>Pseudomonas aeruginosa</i> PB1-like broad host range phage under simulated infection conditions. <b>2010</b> , 10, 301		51
347	Bacteriophages of <i>Pseudomonas</i> . <b>2010</b> , 5, 1041-55		68
346	Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives. <b>2011</b> , 25, 347-55		21
345	Genomic and proteomic characterization of the broad-host-range <i>Salmonella</i> phage PVP-SE1: creation of a new phage genus. <b>2011</b> , 85, 11265-73		73
344	Phage therapy: delivering on the promise. <b>2011</b> , 2, 935-47		23
343	Fighting bacterial infections-future treatment options. <b>2011</b> , 14, 125-39		117
342	La phagothérapie: passé et avenir (faits nouveaux et procédure[s] pour une réhabilitation). <b>2011</b> , 26, 165-175		
341	The next generation of bacteriophage therapy. <b>2011</b> , 14, 524-31		223
340	Microbiological and molecular assessment of bacteriophage ISP for the control of <i>Staphylococcus aureus</i> . <i>PLoS ONE</i> , <b>2011</b> , 6, e24418	3.7	70
339	Rapid and quantitative automated measurement of bacteriophage activity against cystic fibrosis isolates of <i>Pseudomonas aeruginosa</i> . <b>2011</b> , 110, 631-40		13
338	Bacteriophages for the treatment of <i>Pseudomonas aeruginosa</i> infections. <b>2011</b> , 111, 1-7		57
337	<i>Salmonella</i> Typhimurium-specific bacteriophage $\Phi$ H19 and the origins of species specificity in the $\Phi$ 101-like phage family. <b>2011</b> , 8, 498		37
336	Application of a bacteriophage cocktail to reduce <i>Salmonella</i> Typhimurium U288 contamination on pig skin. <b>2011</b> , 151, 157-63		114

335	Modified phages: novel antimicrobial agents to combat infectious diseases. <b>2011</b> , 29, 732-8	26
334	Antibacterial efficacy of lytic <i>Pseudomonas</i> bacteriophage in normal and neutropenic mice models. <b>2011</b> , 49, 994-9	44
333	The phage therapy paradigm: pre-emptive or sur-mesure?. <b>2011</b> , 28, 934-7	188
332	Efficacy of polyvalent bacteriophage P-27/HP to control multidrug resistant <i>Staphylococcus aureus</i> associated with human infections. <b>2011</b> , 62, 255-60	48
331	Bacteriophages as twenty-first century antibacterial tools for food and medicine. <b>2011</b> , 90, 851-9	58
330	Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. <b>2011</b> , 100, 5197-205	89
329	Phage treatment of human infections. <b>2011</b> , 1, 66-85	577
328	Pros and cons of phage therapy. <b>2011</b> , 1, 111-114	451
327	The Staphylococci phages family: an overview. <i>Viruses</i> , <b>2012</b> , 4, 3316-35	6.2 122
326	Development of a high throughput assay for indirectly measuring phage growth using the OmniLog(TM) system. <b>2012</b> , 2, 159-167	46
325	Effects of sequential and simultaneous applications of bacteriophages on populations of <i>Pseudomonas aeruginosa</i> in vitro and in wax moth larvae. <b>2012</b> , 78, 5646-52	92
324	Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 <i>Escherichia coli</i> strain producing CTX-M-15. <b>2012</b> , 56, 3568-75	79
323	Introducing yesterday's phage therapy in today's medicine. <b>2012</b> , 7, 379-390	58
322	Next generation sequencing technologies and the changing landscape of phage genomics. <b>2012</b> , 2, 190-199	44
321	Advances in bacteriophage-mediated control of plant pathogens. <b>2012</b> , 2012, 326452	89
320	Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications. <b>2012</b> , 13, 699-722	151
319	In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model. <b>2012</b> , 56, 949-54	27
318	<i>Pseudomonas</i> biofilms, cystic fibrosis, and phage: a silver lining?. <b>2012</b> , 3,	17

317	What is needed for phage therapy to become a reality in Western medicine?. <b>2012</b> , 434, 138-42	100
316	Phage therapy--history from Twort and d'Herelle through Soviet experience to current approaches. <b>2012</b> , 83, 3-40	158
315	<i>Pseudomonas aeruginosa</i> population structure revisited under environmental focus: impact of water quality and phage pressure. <b>2012</b> , 14, 1952-67	75
314	Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. <b>2012</b> , 434, 222-32	150
313	CIM( ) monolithic anion-exchange chromatography as a useful alternative to CsCl gradient purification of bacteriophage particles. <b>2012</b> , 434, 265-70	54
312	Cangene gold medal award lecture - Genomic analysis and modification of <i>Burkholderia cepacia</i> complex bacteriophages. <b>2012</b> , 58, 221-35	7
311	<i>Pseudomonas aeruginosa</i> bacteriophage PA1 requires type IV pili for infection and shows broad bactericidal and biofilm removal activities. <b>2012</b> , 78, 6380-5	42
310	Rapid identification of international multidrug-resistant <i>Pseudomonas aeruginosa</i> clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages. <b>2012</b> , 56, 6175-80	17
309	Novel therapeutic strategies to counter <i>Pseudomonas aeruginosa</i> infections. <b>2012</b> , 10, 219-35	42
308	Genomics of staphylococcal Twort-like phages--potential therapeutics of the post-antibiotic era. <b>2012</b> , 83, 143-216	86
307	Bacteriophage therapy: practicability and clinical need meet in the multidrug-resistance era. <b>2012</b> , 7, 797-9	12
306	Phage therapy to control multidrug-resistant <i>Pseudomonas aeruginosa</i> skin infections: in vitro and ex vivo experiments. <b>2012</b> , 31, 3241-9	62
305	Synergistic action of gentamicin and bacteriophage in a continuous culture population of <i>Staphylococcus aureus</i> . <i>PLoS ONE</i> , <b>2012</b> , 7, e51017	3-7 67
304	The promise of bacteriophage therapy for <i>Burkholderia cepacia</i> complex respiratory infections. <b>2011</b> , 1, 27	24
303	Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. <b>2012</b> , 60, 161-72	55
302	Isolation and characterization of wide host range lytic bacteriophage AP22 infecting <i>Acinetobacter baumannii</i> . <b>2012</b> , 332, 40-6	38
301	Characterization of a bacteriophage, isolated from a cow with mastitis, that is lytic against <i>Staphylococcus aureus</i> strains. <b>2012</b> , 157, 225-34	57
300	Bacteriophage-host interaction: from splendid isolation into a messy reality. <b>2013</b> , 16, 500-6	39

299	Respirable bacteriophages for the treatment of bacterial lung infections. <b>2013</b> , 26, 317-35	35
298	Novel avenues for Clostridium difficile infection drug discovery. <b>2013</b> , 8, 459-77	13
297	Genomic characterization of JG068, a novel virulent podovirus active against Burkholderia cenocepacia. <b>2013</b> , 14, 574	16
296	Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. <b>2013</b> , 443, 187-96	152
295	Applying insights from biofilm biology to drug development - can a new approach be developed?. <b>2013</b> , 12, 791-808	340
294	Bacteriophage therapy against staphylococci. <b>2013</b> , 60, 411-22	8
293	Predation in homogeneous and heterogeneous phage environments affects virulence determinants of Pseudomonas aeruginosa. <b>2013</b> , 79, 2862-71	39
292	Treatment, promotion, commotion: antibiotic alternatives in food-producing animals. <b>2013</b> , 21, 114-9	172
291	Phage cocktails and the future of phage therapy. <b>2013</b> , 8, 769-83	484
290	Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applications. <b>2013</b> , 87, 3237-47	62
289	Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies. <i>PLoS ONE</i> , <b>2013</b> , 8, e75380	3.7 30
288	Isolation, Culture, and Characterization of Bacteriophages. <b>2013</b> , 7, 4.4.1	3
287	Evolution of Pseudomonas aeruginosa virulence as a result of phage predation. <b>2013</b> , 79, 6110-6	47
286	Phage Therapy. <b>2013</b> , 191-231	4
285	Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). <i>PLoS ONE</i> , <b>2013</b> , 8, e68397	76
284	Phage renaissance: new hope against antibiotic resistance. <b>2013</b> , 121, a48-53	20
283	A Virulent Salmonella enterica Serovar Enteritidis Phage SE2 with a Strong Bacteriolytic Activity of Planktonic and Biofilmed Cells. <b>2013</b> , 43, 186	9
282	Contrasted coevolutionary dynamics between a bacterial pathogen and its bacteriophages. <b>2014</b> , 111, 11109-14	71

- 281 Bacteriophage: The Viruses Infecting Bacteria and Their Multiple Applications. **2014**,
- 280 Phages can constrain protist predation-driven attenuation of *Pseudomonas aeruginosa* virulence in multienemy communities. **2014**, 8, 1820-30 23
- 279 Experimental protection of diabetic mice against Lethal *P. aeruginosa* infection by bacteriophage. **2014**, 2014, 793242 16
- 278 Characterization, sequencing and comparative genomic analysis of vB\_AbaM-IME-AB2, a novel lytic bacteriophage that infects multidrug-resistant *Acinetobacter baumannii* clinical isolates. **2014**, 14, 181 43
- 277 Characterization of newly isolated lytic bacteriophages active against *Acinetobacter baumannii*. *PLoS ONE*, **2014**, 9, e104853 3-7 59
- 276 Stability and purity of a bacteriophage cocktail preparation for nebulizer delivery. **2014**, 58, 118-22 34
- 275 Efficiency of phage cocktails in the inactivation of *Vibrio* in aquaculture. **2014**, 424-425, 167-173 91
- 274 Bactericidal genes of Staphylococcal bacteriophage Sb-1. **2014**, 68, 204-10 8
- 273 Call for a dedicated European legal framework for bacteriophage therapy. **2014**, 62, 117-29 59
- 272 Hard surfaces decontamination of enteropathogenic and Shiga toxin-producing *Escherichia coli* using bacteriophages. **2014**, 57, 123-129 19
- 271 Aerosol phage therapy efficacy in *Burkholderia cepacia* complex respiratory infections. **2014**, 58, 4005-13 68
- 270 Viruses versus bacteria—novel approaches to phage therapy as a tool against multidrug-resistant pathogens. **2014**, 69, 2326-36 136
- 269 A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. **2014**, 5, 226-35 289
- 268 Susceptibility of extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* to commercially available and laboratory-isolated bacteriophages. **2014**, 69, 1148-50 7
- 267 Phage therapy—constraints and possibilities. **2014**, 119, 192-8 109
- 266 Genetic and molecular principles for the selection of *Pseudomonas* and *Staphylococcus* therapeutic bacteriophages. **2014**, 50, 306-312 2
- 265 In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms causing diabetic foot infections. **2014**, 63, 1055-1065 47
- 264 Bacteriophage therapy of a *Vibrio parahaemolyticus* infection caused by a multiple-antibiotic-resistant O3:K6 pandemic clinical strain. **2014**, 210, 72-8 63

263	A simple and novel modification of comet assay for determination of bacteriophage mediated bacterial cell lysis. <b>2014</b> , 203, 33-8		5
262	Isolation and partial characterization of bacteriophages infecting <i>Pseudomonas syringae</i> pv. actinidiae, causal agent of kiwifruit bacterial canker. <b>2014</b> , 54, 1210-21		38
261	Phage-based nanomaterials for biomedical applications. <b>2014</b> , 10, 1741-50		42
260	Bacteriophage: Therapeutic Uses. <b>2014</b> ,		3
259	Virus Production Under Suspension Conditions. <b>2014</b> , 503-554		
258	Bacteriophage reduces biofilm of <i>Staphylococcus aureus</i> ex vivo isolates from chronic rhinosinusitis patients. <b>2014</b> , 28, 3-11		45
257	The isolation and characterization of two <i>Stenotrophomonas maltophilia</i> bacteriophages capable of cross-taxonomic order infectivity. <b>2015</b> , 16, 664		28
256	Bacteriophages and phage-derived proteins--application approaches. <b>2015</b> , 22, 1757-73		110
255	Bacteriophage-based therapy in cystic fibrosis-associated <i>Pseudomonas aeruginosa</i> infections: rationale and current status. <b>2015</b> , 9, 3653-63		35
254	Phage Pan70, a Putative Temperate Phage, Controls <i>Pseudomonas aeruginosa</i> in Planktonic, Biofilm and Burn Mouse Model Assays. <i>Viruses</i> , <b>2015</b> , 7, 4602-23	6.2	31
253	On-Demand Isolation of Bacteriophages Against Drug-Resistant Bacteria for Personalized Phage Therapy. <b>2015</b> , 6, 1271		79
252	Removal of endotoxins from bacteriophage preparations by extraction with organic solvents. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122672	3.7	60
251	Strain Specific Phage Treatment for <i>Staphylococcus aureus</i> Infection Is Influenced by Host Immunity and Site of Infection. <i>PLoS ONE</i> , <b>2015</b> , 10, e0124280	3.7	47
250	Unexploited opportunities for phage therapy. <b>2015</b> , 6, 180		35
249	Bacteriophage Therapy: Advances in Formulation Strategies and Human Clinical Trials. <b>2015</b> , 2, 599-618		91
248	Phage approved in food, why not as a therapeutic?. <b>2015</b> , 13, 91-101		48
247	Isolation and characterization of T7-like lytic bacteriophages infecting multidrug resistant <i>Pseudomonas aeruginosa</i> isolated from Egypt. <b>2015</b> , 70, 786-91		10
246	Phage Therapy: a Step Forward in the Treatment of <i>Pseudomonas aeruginosa</i> Infections. <b>2015</b> , 89, 7449-56		80

245	Bacteriophage therapy: history and future prospects. <b>2015</b> , 10, 449-461	21
244	Bacteriophage Delivery by Nebulization and Efficacy Against Phenotypically Diverse <i>Pseudomonas aeruginosa</i> from Cystic Fibrosis Patients. <b>2015</b> , 28, 353-60	36
243	In vitro and in vivo antibacterial activity of environmental bacteriophages against <i>Pseudomonas aeruginosa</i> strains from cystic fibrosis patients. <b>2015</b> , 99, 6021-33	39
242	Bacteriophage-based Products and Techniques for Identification of Biological Pathogens. <b>2015</b> , 17-33	2
241	Genome modifications and cloning using a conjugally transferable recombineering system. <b>2015</b> , 8, 24-35	8
240	Modeling tailed bacteriophage adsorption: Insight into mechanisms. <b>2015</b> , 485, 355-62	38
239	Phage on tap-a quick and efficient protocol for the preparation of bacteriophage laboratory stocks. <b>2016</b> , 4, e2261	112
238	Small Colony Variants and Single Nucleotide Variations in Pf1 Region of PB1 Phage-Resistant <i>Pseudomonas aeruginosa</i> . <b>2016</b> , 7, 282	11
237	Morphologically Distinct <i>Escherichia coli</i> Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release In Vitro. <b>2016</b> , 7, 437	21
236	The Developing World Urgently Needs Phages to Combat Pathogenic Bacteria. <b>2016</b> , 7, 882	42
235	Commentary: Morphologically Distinct <i>Escherichia coli</i> Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release In Vitro. <b>2016</b> , 7, 1029	10
234	Bacteriophage Procurement for Therapeutic Purposes. <b>2016</b> , 7, 1177	76
233	A Partially Purified <i>Acinetobacter baumannii</i> Phage Preparation Exhibits no Cytotoxicity in 3T3 Mouse Fibroblast Cells. <b>2016</b> , 7, 1198	10
232	Effectiveness of Commercial Bacteriophage Cocktails on Diverse Extended-Spectrum Beta-Lactamase Producing Strains. <b>2016</b> , 7, 1761	10
231	Response: Commentary: Morphologically Distinct Bacteriophages Differ in Their Efficacy and Ability to Stimulate Cytokine Release. <b>2016</b> , 7, 1974	1
230	Characterization of <i>Pseudomonas aeruginosa</i> Phage C11 and Identification of Host Genes Required for Virion Maturation. <b>2016</b> , 6, 39130	11
229	Surface topological differences of phage infected uropathogenic (UPEC) strains, revealed by atomic force microscopy. <b>2016</b> , 5, 2112	2
228	Therapeutic effect of <i>Pseudomonas aeruginosa</i> phage YH30 on mink hemorrhagic pneumonia. <b>2016</b> , 190, 5-11	17



227	Intranasal treatment with bacteriophage rescues mice from <i>Acinetobacter baumannii</i> -mediated pneumonia. <b>2016</b> , 11, 631-41	31
226	Review on bacterial biofilm: An universal cause of contamination. <b>2016</b> , 7, 56-66	79
225	Alternatives to overcoming bacterial resistances: State-of-the-art. <b>2016</b> , 191, 51-80	147
224	Bacteriophages with potential to inactivate <i>Salmonella Typhimurium</i> : Use of single phage suspensions and phage cocktails. <b>2016</b> , 220, 179-92	59
223	Overview of Bacteriophage Lifecycles and Applications. <b>2016</b> , 1-8	
222	Parasite diversity drives rapid host dynamics and evolution of resistance in a bacteria-phage system. <b>2016</b> , 70, 969-78	20
221	Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with <i>Pseudomonas aeruginosa</i> cystic fibrosis bacterial isolates. <b>2016</b> , 29, 188-98	55
220	The complete genome sequence of PE3-1, a novel <i>E. coli</i> O153 phage. <b>2016</b> , 161, 3291-4	
219	Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. <b>2016</b> , 25, S27-S33	108
218	Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos. <b>2016</b> , 106, 45-62	86
217	Inhalation Study of Mycobacteriophage D29 Aerosol for Mice by Endotracheal Route and Nose-Only Exposure. <b>2016</b> , 29, 393-405	22
216	Efficacy of two <i>Staphylococcus aureus</i> phage cocktails in cheese production. <b>2016</b> , 217, 7-13	25
215	A bacteriophage journey at the European Medicines Agency. <b>2016</b> , 363, fnv225	47
214	Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework. <b>2016</b> , 363,	9
213	Nature knows best: employing whole microbial strategies to tackle antibiotic resistant pathogens. <b>2017</b> , 9, 47-49	7
212	Syndemics and the biosocial conception of health. <b>2017</b> , 389, 941-950	506
211	Phage engineering: how advances in molecular biology and synthetic biology are being utilized to enhance the therapeutic potential of bacteriophages. <b>2017</b> , 5, 42-54	16
210	Bacteriophage Biodefense. <b>2017</b> , 193-222	1

209	Endotoxin Removal from Escherichia coli Bacterial Lysate Using a Biphasic Liquid System. <b>2017</b> , 1600, 107-112	6
208	Phage therapy for the treatment of human intestinal bacterial infections: soon to be a reality?. <b>2017</b> , 11, 785-788	17
207	Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. <b>2017</b> , 249, 100-133	200
206	Bacteriophage and Antimicrobial Resistance. <b>2017</b> , 19-57	3
205	Assessment of phage cocktails with extended host range activity against antibiotic resistant strains of Pseudomonas aeruginosa. <b>2017</b> , 26, 417-422	5
204	Phages Against Infectious Diseases. <b>2017</b> , 269-294	3
203	Characterization and genomic study of "phiKMV-Like" phage PAXYB1 infecting Pseudomonas aeruginosa. <b>2017</b> , 7, 13068	12
202	Bacteriophages: the possible solution to treat infections caused by pathogenic bacteria. <b>2017</b> , 63, 865-879	41
201	Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. <b>2017</b> , 7, 8004	101
200	The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways. <b>2017</b> , 16, 663-670	31
199	Clinical Antibiotic-resistant Acinetobacter baumannii Strains with Higher Susceptibility to Environmental Phages than Antibiotic-sensitive Strains. <b>2017</b> , 7, 6319	33
198	Pseudomonas predators: understanding and exploiting phage-host interactions. <b>2017</b> , 15, 517-530	94
197	[Beyond antibiotic therapy - Future antiinfective strategies - Update 2017]. <b>2017</b> , 120, 573-584	18
196	Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. <b>2017</b> , 21, 129	135
195	Isolation of bacteriophages and their application to control Pseudomonas aeruginosa in planktonic and biofilm models. <b>2017</b> , 168, 194-207	26
194	Bacteriophages and its applications: an overview. <b>2017</b> , 62, 17-55	66
193	Control of Multidrug-Resistant Gene Flow in the Environment Through Bacteriophage Intervention. <b>2017</b> , 181, 1007-1029	17
192	Bacterial competition and quorum-sensing signalling shape the eco-evolutionary outcomes of model phage therapy. <b>2017</b> , 10, 161-169	17

191	The role of staphylococci in subclinical mastitis of cows and lytic phage isolation against to. <b>2017</b> , 10, 1481-1485	6
190	Physiology and Pathology of Multidrug-Resistant Bacteria: Phage-Related Therapy. <b>2017</b> ,	
189	Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. <b>2017</b> , 8, 162-173	340
188	Characterization of vB_SauM-fRuSau02, a Twort-Like Bacteriophage Isolated from a Therapeutic Phage Cocktail. <i>Viruses</i> , <b>2017</b> , 9,	6.2 31
187	Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. <b>2017</b> , 17, 90	82
186	Effect of dilution rate on productivity of continuous bacteriophage production in cellstat. <b>2018</b> , 102, 3649-3661	15
185	Bacteriophages are more virulent to bacteria with human cells than they are in bacterial culture; insights from HT-29 cells. <b>2018</b> , 8, 5091	48
184	Phage Aggregation-Dispersion by Ions: Striving beyond Antibacterial Therapy. <b>2018</b> , 36, 875-881	11
183	Staphylococcus aureus controls interleukin-5 release in upper airway inflammation. <b>2018</b> , 180, 53-60	17
182	Piperacillin and ceftazidime produce the strongest synergistic phage-antibiotic effect in <i>Pseudomonas aeruginosa</i> . <b>2018</b> , 163, 1941-1948	31
181	Methods for Bacteriophage Preservation. <b>2018</b> , 1693, 219-230	10
180	Bacteriophage Production in Compliance with Regulatory Requirements. <b>2018</b> , 1693, 233-252	21
179	Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis. <b>2018</b> , 9, 1330	16
178	Cross-resistance is modular in bacteria-phage interactions. <b>2018</b> , 16, e2006057	46
177	The disparate effects of bacteriophages on antibiotic-resistant bacteria. <b>2018</b> , 7, 168	65
176	Bacteriophages Synergize with the Gut Microbial Community To Combat. <b>2018</b> , 3,	8
175	Bacteriophages and phage products: Applications in medicine and biotechnological industries, and general concerns. <b>2018</b> , 13, 55-70	4
174	Characterization and genome analysis of novel phage vB_EfaP_IME195 infecting <i>Enterococcus faecalis</i> . <b>2018</b> , 54, 804-811	14

173	The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue. <b>2018</b> , 6,		41
172	Applications of Bacteriophages in the Treatment of Localized Infections in Humans. <b>2018</b> , 9, 1696		64
171	Phage Therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant in Mice. <b>2017</b> , 8, 2659		68
170	Two New Lytic Bacteriophages of the Family Against Carbapenem-Resistant. <b>2018</b> , 9, 850		32
169	Identification and Characterization of Type IV Pili as the Cellular Receptor of Broad Host Range Bacteriophages DLP1 and DLP2. <i>Viruses</i> , <b>2018</b> , 10,	6.2	24
168	Phage therapy for respiratory infections. <b>2018</b> , 133, 76-86		66
167	Electrophoretic techniques for purification, separation and detection of Kayvirus with subsequent control by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and microbiological methods. <b>2018</b> , 1570, 155-163		9
166	Phage on Tap: A Quick and Efficient Protocol for the Preparation of Bacteriophage Laboratory Stocks. <b>2018</b> , 1838, 37-46		8
165	Phage therapy: progress in pharmacokinetics. <b>2018</b> , 54,		13
164	Non-antibiotic antimicrobial interventions and antimicrobial stewardship in wound care. <b>2018</b> , 27, 355-377		18
163	Factors determining phage stability/activity: challenges in practical phage application. <b>2019</b> , 17, 583-606		26
162	The Removal of Endo- and Enterotoxins From Bacteriophage Preparations. <b>2019</b> , 10, 1674		28
161	Characterization of the Three New Kayviruses and Their Lytic Activity Against Multidrug-Resistant. <i>Microorganisms</i> , <b>2019</b> , 7,	4.9	16
160	Correlation of Host Range Expansion of Therapeutic Bacteriophage Sb-1 with Allele State at a Hypervariable Repeat Locus. <b>2019</b> , 85,		19
159	Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2). <b>2019</b> , 9, 13893		10
158	Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. <i>Viruses</i> , <b>2019</b> , 11,	6.2	50
157	Robust Approaches for the Production of Active Ingredient and Drug Product for Human Phage Therapy. <b>2019</b> , 10, 2289		19
156	Bacteriophage interactions with mammalian tissue: Therapeutic applications. <b>2019</b> , 145, 4-17		64

155	Design and Preclinical Development of a Phage Product for the Treatment of Antibiotic-Resistant Infections. <i>Viruses</i> , <b>2019</b> , 11,	6.2	75
154	Isolation and characterization of a bacteriophage and its potential to disrupt multi-drug resistant <i>Pseudomonas aeruginosa</i> biofilms. <i>Microbial Pathogenesis</i> , <b>2019</b> , 128, 329-336	3.8	32
153	Protective and therapeutic application of the depolymerase derived from a novel KN1 genotype of <i>Klebsiella pneumoniae</i> bacteriophage in mice. <b>2019</b> , 170, 156-164		21
152	Mini-review: efficacy of lytic bacteriophages on multispecies biofilms. <b>2019</b> , 35, 472-481		19
151	Effect of serum anti-phage activity on colibacillosis control by repeated phage therapy in broilers. <b>2019</b> , 234, 61-71		8
150	Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights. <b>2019</b> , 12, 635-642		21
149	Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory. <b>2019</b> , 57,		10
148	Efficacy and safety assessment of two enterococci phages in an in vitro biofilm wound model. <b>2019</b> , 9, 6643		32
147	Processing Phage Therapy Requests in a Brussels Military Hospital: Lessons Identified. <i>Viruses</i> , <b>2019</b> , 11,	6.2	38
146	Antibiofilm potential of purified environmental bacteriophage preparations against early stage <i>Pseudomonas aeruginosa</i> biofilms. <b>2019</b> , 126, 1657-1667		11
145	Efficiency of Single Phage Suspensions and Phage Cocktail in the Inactivation of and Typhimurium: An Preliminary Study. <i>Microorganisms</i> , <b>2019</b> , 7,	4.9	34
144	Mechanistic research holds promise for bacterial vaccines and phage therapies for. <b>2019</b> , 13, 909-924		17
143	The Gut Microbiota as a Therapeutic Approach for Obesity. <b>2019</b> , 227-234		0
142	Pharmacological and Immunological Aspects of Phage Therapy. <b>2019</b> , 1, 34-42		11
141	Clinical Implications of <i>Pseudomonas aeruginosa</i> : Antibiotic Resistance, Phage & Antimicrobial Peptide Therapy. <b>2019</b> , 13, 65-86		2
140	A novel wound dressing consisting of PVA-SA hybrid hydrogel membrane for topical delivery of bacteriophages and antibiotics. <b>2019</b> , 572, 118779		57
139	Exploring the whole standard operating procedure for phage therapy in clinical practice. <b>2019</b> , 17, 373		14
138	Bacteriophage production processes. <b>2019</b> , 103, 685-694		21

137	Antibiotic resistance in <i>Pseudomonas aeruginosa</i> : mechanisms and alternative therapeutic strategies. <b>2019</b> , 37, 177-192		463
136	Synergistic effect of phage therapy using a cocktail rather than a single phage in the control of severe colibacillosis in quails. <b>2019</b> , 98, 653-663		14
135	The Virulence Index: A Metric for Quantitative Analysis of Phage Virulence. <b>2020</b> , 1, 27-36		18
134	Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo. <b>2020</b> , 108, 39-49		30
133	Phage therapy for severe bacterial infections: a narrative review. <b>2020</b> , 212, 279-285		15
132	Therapeutic bacteriophages as a rescue treatment for drug-resistant infections - an in vivo studies overview. <b>2020</b> , 128, 985-1002		11
131	Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy. <b>2020</b> , 7, 559-587		8
130	Bacteriophage biocontrol to fight <i>Listeria</i> outbreaks in seafood. <b>2020</b> , 145, 111682		8
129	New Phage cocktail against infantile Sepsis bacteria. <i>Microbial Pathogenesis</i> , <b>2020</b> , 148, 104447	3.8	4
128	Rapid Isolation, Propagation, and Online Analysis of a Small Number of Therapeutic Staphylococcal Bacteriophages from a Complex Matrix. <b>2020</b> , 6, 2745-2755		3
127	The Rationale for Using Bacteriophage to Treat and Prevent Periprosthetic Joint Infections. <b>2020</b> , 11, 591021		5
126	Preparative Purification of <i>Pseudomonas aeruginosa</i> Bacteriophages via the Combination of Gel-Permeation and Anion-Exchange Chromatography. <b>2020</b> , 56, 685-691		
125	Characterization of Isolates from Various Geographical Regions of the Caucasus and Their Susceptibility to Bacteriophages. <i>Viruses</i> , <b>2020</b> , 12,	6.2	3
124	Current challenges and future opportunities of phage therapy. <b>2020</b> , 44, 684-700		39
123	PhageScore: A simple method for comparative evaluation of bacteriophages lytic activity. <b>2020</b> , 161, 107652		4
122	Identification of a novel phage targeting methicillin-resistant <i>Staphylococcus aureus</i> In vitro and In vivo. <i>Microbial Pathogenesis</i> , <b>2020</b> , 149, 104317	3.8	6
121	Therapeutic applications of lytic phages in human medicine. <i>Microbial Pathogenesis</i> , <b>2020</b> , 142, 104048	3.8	16
120	Bacteriophage-mediated interference of the c-di-GMP signalling pathway in <i>Pseudomonas aeruginosa</i> . <b>2021</b> , 14, 967-978		5

119	Phenotypic Characterization and Whole-Genome Analysis of a Novel Bacteriophage HCF1 Infecting and. <b>2021</b> , 12, 644013		2
118	Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier. <b>2021</b> , 14,		9
117	A Case of Phage Therapy against Pandrug-Resistant in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. <i>Viruses</i> , <b>2021</b> , 13,	6.2	21
116	Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis. <b>2021</b> , 22,		3
115	Clinical Trials of Bacteriophage Therapeutics. <b>2021</b> , 1099-1127		3
114	Bacteriophage-Delivering Hydrogels: Current Progress in Combating Antibiotic Resistant Bacterial Infection. <b>2021</b> , 10,		14
113	Clinical Phage Microbiology: A suggested in-vitro framework for phage therapy.		0
112	The role of vaccines in combatting antimicrobial resistance. <b>2021</b> , 19, 287-302		58
111	Improving the Inhibitory Effect of Phages against Isolated from a Burn Patient Using a Combination of Phages and Antibiotics. <i>Viruses</i> , <b>2021</b> , 13,	6.2	5
110	Locally isolated broad host-range bacteriophage kills methicillin-resistant <i>Staphylococcus aureus</i> in an in vivo skin excisional wound model in mice. <i>Microbial Pathogenesis</i> , <b>2021</b> , 152, 104744	3.8	5
109	Two Novel Bacteriophages Control Multidrug- and Methicillin-Resistant Biofilm. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 524059	4.9	3
108	Isolation, characterization, and application of phage KM16 against biofilm. <b>2021</b> , 37, 276-288		1
107	The evolutionary trade-offs in phage-resistant <i>Klebsiella pneumoniae</i> entail cross-phage sensitization and loss of multidrug resistance. <b>2021</b> ,		13
106	Bacteriophage manipulation of the microbiome associated with tumour microenvironments-can this improve cancer therapeutic response?. <b>2021</b> , 45,		2
105	Combatting intracellular pathogens using bacteriophage delivery. <b>2021</b> , 47, 461-478		2
104	How to kill <i>Pseudomonas</i> -emerging therapies for a challenging pathogen. <b>2021</b> , 1496, 59-81		2
103	Therapeutic Efficacy of Bacteriophages.		0
102	Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium. <i>Viruses</i> , <b>2021</b> , 13,	6.2	7

101	Bacteriophage Therapy for Critical and High-Priority Antibiotic-Resistant Bacteria and Phage Cocktail-Antibiotic Formulation Perspective. <b>2021</b> , 13, 433-446		4
100	Development of thermosensitive hydrogel wound dressing containing Acinetobacter baumannii phage against wound infections. <b>2021</b> , 602, 120508		7
99	Manufacturing of bacteriophages for therapeutic applications. <b>2021</b> , 49, 107758		3
98	Lytic bacteriophages isolated from limestone caves for biocontrol of Pseudomonas aeruginosa. <b>2021</b> , 34, 102011		0
97	Overview of the risks of Staphylococcus aureus infections and their control by bacteriophages and bacteriophage-encoded products. <b>2021</b> , 52, 2031-2042		0
96	Advances in Phage Therapy: Targeting the Complex. <i>Viruses</i> , <b>2021</b> , 13,	6.2	2
95	Recent progress towards the implementation of phage therapy in Western medicine. <b>2021</b> ,		11
94	Gēa teknolojilerinde inovatif bir yaklař olarak Bakteriyofajlar		0
93	The Future of Bacteriophage Therapy Will Promote Antimicrobial Susceptibility. <b>2021</b> , 6, e0021821		2
92	Isolation, Genomic Analysis, and Preliminary Application of a Bovine Bacteriophage vB_Kpn_B01. <b>2021</b> , 8, 622049		2
91	A Case of In Situ Phage Therapy against in a Bone Allograft Polymicrobial Biofilm Infection: Outcomes and Phage-Antibiotic Interactions. <i>Viruses</i> , <b>2021</b> , 13,	6.2	1
90	ISOLATION OF NEWLY ISOLATED VB_K1 BACTERIOPHAGE AND INVESTIGATION OF SUSCEPTIBILITY ON ESBL POSITIVE KLEBSIELLA SPP. STRAINS. 515-523		
89	Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections. <i>Viruses</i> , <b>2021</b> , 13,	6.2	1
88	Observational case studies of the effect of phage laden Ganga water on psoriasis. <b>2021</b> , 7, 186-190		0
87	Bacteriophage Rescue Therapy of a Vancomycin-Resistant Infection in a One-Year-Old Child following a Third Liver Transplantation. <i>Viruses</i> , <b>2021</b> , 13,	6.2	6
86	Manufacturing Bacteriophages (Part 1 of 2): Cell Line Development, Upstream, and Downstream Considerations. <b>2021</b> , 14,		1
85	The role of phage therapy in burn wound infection management: advantages and pitfalls. <b>2021</b> ,		3
84	Comparison of methods for purification of bacteriophage lysates of gram-negative bacteria for personalized therapy. <b>2021</b> ,		



83	Morphological, biological, and genomic characterization of a newly isolated lytic phage Sfk20 infecting <i>Shigella flexneri</i> , <i>Shigella sonnei</i> , and <i>Shigella dysenteriae</i> 1. <b>2021</b> , 11, 19313		0
82	Parallel evolution of phage resistance - virulence trade - offs during in vitro and nasal <i>Pseudomonas aeruginosa</i> phage treatment.		0
81	Clinical Phage Microbiology: a suggested framework and recommendations for the in-vitro matching steps of phage therapy.. <b>2021</b> , 2, e555-e563		7
80	Antibiotic Replacement Therapy: Phage Therapy. <b>2021</b> , 10, 30-42		
79	Isolation of Bacteriophages. <b>2021</b> , 433-464		2
78	The Selection and Optimization of Phage Hosts. <b>2021</b> , 689-698		0
77	Phage Therapy of Human Bacterial Infections: A Systematic Review. <b>2021</b> , 663-692		1
76	How to Achieve a Good Phage Therapy Clinical Trial?. <b>2019</b> , 147-168		3
75	Isolation of Bacteriophages. <b>2019</b> , 1-32		2
74	Clinical Trials of Bacteriophage Therapeutics. <b>2017</b> , 1-29		2
73	Gut microbiome and multiple sclerosis: New insights and perspective. <b>2020</b> , 88, 107024		10
72	phage kills enteroaggregative without human microbiome dysbiosis. <b>2020</b> , 69, 309-323		12
71	<i>Pseudomonas aeruginosa</i> keratitis in mice: effects of topical bacteriophage KPP12 administration. <i>PLoS ONE</i> , <b>2012</b> , 7, e47742	3-7	54
70	Selection and characterization of a candidate therapeutic bacteriophage that lyses the <i>Escherichia coli</i> O104:H4 strain from the 2011 outbreak in Germany. <i>PLoS ONE</i> , <b>2012</b> , 7, e52709	3-7	37
69	Population dynamics of a <i>Salmonella</i> lytic phage and its host: implications of the host bacterial growth rate in modelling. <i>PLoS ONE</i> , <b>2014</b> , 9, e102507	3-7	40
68	Characterization of the Newly Isolated Lytic Bacteriophages KTN6 and KT28 and Their Efficacy against <i>Pseudomonas aeruginosa</i> Biofilm. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127603	3-7	53
67	Application of Bacteriophage-containing Aerosol against Nosocomial Transmission of Carbapenem-Resistant <i>Acinetobacter baumannii</i> in an Intensive Care Unit. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168380	3-7	23
66	The isolation and characterization of <i>Stenotrophomonas maltophilia</i> T4-like bacteriophage DLP6. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173341	3-7	10

65	Broad-range lytic bacteriophages that kill <i>Staphylococcus aureus</i> local field strains. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181671	3.7	23
64	Stability of bacteriophages in burn wound care products. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182121	3.7	31
63	Isolation of <i>Escherichia coli</i> specific Lytic Phages from Waste Water and evaluation of its antimicrobial effect In Vitro and Chicken meat. <i>Iranian Journal of Medical Microbiology</i> , <b>2019</b> , 13, 180-193 <sup>0.4</sup>		1
62	Exploring the risks of phage application in the environment. <b>2013</b> , 4, 358		74
61	Chimeric spider silk production in microalgae: a modular bionanomaterial. 2, e9342		4
60	The role of regulated clinical trials in the development of bacteriophage therapeutics. <b>2012</b> , 6, 279-86		66
59	Therapeutic Potential of Staphylococcal Bacteriophages for Nasal Decolonization of <i>Staphylococcus aureus</i> in Mice. <b>2013</b> , 03, 52-60		6
58	Common Preconditions for Safe Phage Therapy of <i>Pseudomonas aeruginosa</i> Infections. <b>2014</b> , 04, 766-773		2
57	Synergy as a rationale for phage therapy using phage cocktails. <b>2014</b> , 2, e590		74
56	Advancing phage therapy through the lens of virus host-breadth and emergence potential. <b>2021</b> , 111, 63-110		0
55	Prospects of using adaptive phage therapy in the rehabilitation of post-COVID-19 patients. <b>2021</b> , 3, 254-259		0
54	Importance of Bacteriophage in Combating Hospital-Acquired Infection (HAI). <b>2014</b> , 05, 1192-1201		
53	Phage Therapy: Bacteriophages as Natural, Self-Replicating Antimicrobials. <b>2015</b> , 883-908		2
52	Biology and ecology of bacteriophages (review). <i>Bulletin Veterinary Biotechnology</i> , <b>2018</b> , 32, 112-121	0.2	
51	DAIRY INDUSTRIAL HYGIENE: A REVIEW ON BIOFILM CHALLENGES AND CONTROL. <i>International Journal of Research -GRANTHAALAYAH</i> , <b>2018</b> , 6, 268-273	0.2	
50	Bacteriophages: A New (Yet Old) Weapon Against Infections. <b>2019</b> , 69-79		
49	Phage Pharmacokinetics: Relationship with Administration Route. <b>2019</b> , 43-57		2
48	The Virulence Index: A Metric for Quantitative Analysis of Phage Virulence.		

47	Detection of Mycobacterium tuberculosis - Microscopy to Molecular Techniques at the Tertiary Care Hospital in Telangana. <i>Iranian Journal of Medical Microbiology</i> , <b>2019</b> , 13, 175-179	0.4	
46	The Selection and Optimization of Phage Hosts. <b>2020</b> , 1-10		
45	Phage Therapy in Cystic Fibrosis. Challenges and Perspectives. <b>2020</b> , 403-461		
44	Experimental phage therapy of burn wound infection: difficult first steps. <i>International Journal of Burns and Trauma</i> , <b>2014</b> , 4, 66-73	0.4	100
43	[Not Available]. <i>Annals of Burns and Fire Disasters</i> , <b>2015</b> , 28, 94-104	0.8	2
42	Phage Therapy: Future Inquiries. <i>Postdoc Journal</i> , <b>2013</b> , 1, 24-35		5
41	[Phage therapy, an alternative to antibiotic therapy?]. <i>Revista Espanola De Quimioterapia</i> , <b>2018</b> , 31, 101-104	1.0	1
40	Bacteriophages in food supplements obtained from natural sources. <i>Acta Biomedica</i> , <b>2020</b> , 91, e2020025,2		
39	Bacteriophages and their potential for treatment of gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	1
38	Fajlarlı Balı Hastalıklarının Kontrolünde Kullanım. <i>Acta Aquatica Turcica</i> ,	0.2	
37	Biological Therapy on Infected Traumatic Wounds: A Case-Control Study.. <i>International Journal of Lower Extremity Wounds</i> , <b>2022</b> , 15347346211072779	1.6	0
36	Novel Bacteriophages Show Activity against Selected Australian Clinical Strains of .. <i>Microorganisms</i> , <b>2022</b> , 10,	4.9	0
35	Phage Therapy as an Alternative Treatment in the Fight Against AMR: Real-World Problems and Possible Futures. <b>2022</b> , 357-374		0
34	The potential of bacteriophage therapy in the treatment of paediatric respiratory infections.. <i>Paediatric Respiratory Reviews</i> , <b>2022</b> ,	4.8	0
33	Phage-based technologies for highly sensitive luminescent detection of foodborne pathogens and microbial toxins: A review.. <i>Comprehensive Reviews in Food Science and Food Safety</i> , <b>2022</b> ,	16.4	3
32	Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection.. <i>Viruses</i> , <b>2021</b> , 13,	6.2	1
31	Isolation, Characterization and Evaluation of Specific Bacteriophages Targeting Extensive Drug Resistance Strains of Isolated from Septic Burn Wounds.. <i>Infection and Chemotherapy</i> , <b>2022</b> , 54, 153-164	3.9	1
30	Parallel evolution of Pseudomonas aeruginosa phage resistance and virulence loss in response to phage treatment and .. <i>ELife</i> , <b>2022</b> , 11,	8.9	2

29	Phenotypic and Genetic Characterization of Phage AhMtk13a and Evaluation of Its Therapeutic Potential on Simulated Infection in .. <i>Viruses</i> , <b>2022</b> , 14,	6.2	0
28	Intracameral Bacteriophage Injection as Postoperative Prophylaxis for Enterococcus faecalis-Induced Endophthalmitis After Cataract Surgery in Rabbits.. <i>Translational Vision Science and Technology</i> , <b>2022</b> , 11, 2	3.3	
27	Multidrug-resistant enteric bacteria in Nigeria and potential use of bacteriophages as biocontrol.. <i>Science of the Total Environment</i> , <b>2022</b> , 153842	10.2	1
26	Adaptive Phage Therapy in the Treatment of Patients with Recurrent Pneumonia (Pilot Study). <i>Obshchaya Reanimatologiya</i> , <b>2021</b> , 17, 4-14	0.8	0
25	Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study.. <i>Microbiology Spectrum</i> , <b>2021</b> , 9, e0173621	8.9	3
24	Image_1.PDF. <b>2018</b> ,		
23	Table_1.DOCX. <b>2018</b> ,		
22	Table_2.DOCX. <b>2018</b> ,		
21	Presentation_1.PDF. <b>2018</b> ,		
20	Table_1.XLSX. <b>2019</b> ,		
19	Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Femur Osteomyelitis-A Case Report.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 851310	4.9	0
18	The comparison of lytic activity of isolated phage and commercial Intesti bacteriophage on ESBL producer E. coli and determination of Ec_P6 phage efficacy with in vivo Galleria mellonella larvae model.. <i>Microbial Pathogenesis</i> , <b>2022</b> , 167, 105563	3.8	1
17	Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. <i>Signal Transduction and Targeted Therapy</i> , <b>2022</b> , 7,	21	11
16	In Vitro Techniques and Measurements of Phage Characteristics That Are Important for Phage Therapy Success. <i>Viruses</i> , <b>2022</b> , 14, 1490	6.2	2
15	One-step salting-out extraction of bacteriophage from its infection broth of Acinetobacter baumannii. <b>2022</b> , 1679, 463407		0
14	Monitoring phage-induced lysis of Gram-negatives in real time using a fluorescent DNA dye.		0
13	Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. <b>2022</b> , 13,		2
12	Review of bacteriophage and its applications. <b>2022</b> , 8, 133-147		0

11	Isolation and Characterization of Lytic <i>Pseudomonas aeruginosa</i> Bacteriophages Isolated from Sewage Samples from Tunisia. <b>2022</b> , 14, 2339	0
10	Isolation and Characterization of Lytic Bacteriophages Active against Clinical Strains of <i>E. coli</i> and Development of a Phage Antimicrobial Cocktail. <b>2022</b> , 14, 2381	1
9	Alginate chitosan microbeads and thermos-responsive hyaluronic acid hydrogel for phage delivery. <b>2022</b> , 103991	0
8	Characteristics of a novel temperate bacteriophage against <i>Staphylococcus arlettae</i> (vB_SarS_BM31).	0
7	Tracking the phage trends: A comprehensive review of applications in therapy and food production. 13,	0
6	Les virus au service de la santé: les bactériophages. <b>2022</b> , 38, 1043-1051	0
5	A novel virulent Litonavirus phage possesses therapeutic value against multidrug resistant <i>Pseudomonas aeruginosa</i> . <b>2022</b> , 12,	0
4	Monitoring phage-induced lysis of gram-negatives in real time using a fluorescent DNA dye. <b>2023</b> , 13,	2
3	Coping with the ESKAPE pathogens: Evolving strategies, challenges and future prospects. <b>2023</b> , 175, 105963	0
2	Phage Therapy as an Alternative Treatment Modality for Resistant <i>Staphylococcus aureus</i> Infections. <b>2023</b> , 12, 286	1
1	A Century of Clinical Use of Phages: A Literature Review. <b>2023</b> , 12, 751	0